|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
SEER 5-year relative survival rate,
2012–2018, . Cancer Statistics Explorer Network. National Cancer
Institute; United States: https://seer.cancer.gov/statistics-network/explorer/application.htmlApril
1–2023
|
|
3
|
Cancer Information Service, National
Cancer Center, Japan and National Cancer Registry (In Japanese)
(Ministry of Health, Labour and Welfare), . https://ganjoho.jp/reg_stat/statistics/data/dl/en.htmlApril
1–2023
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Okusaka T, Ikeda M, Fukutomi A, Ioka T,
Furuse J, Ohkawa S, Isayama H and Boku N: Phase II study of
FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic
pancreatic cancer. Cancer Sci. 105:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M,
Uesugi K, Sata N, Miyashita K, Mizuno N, Tsuji K, et al: A phase II
study of modified FOLFIRINOX for chemotherapy-naïve patients with
metastatic pancreatic cancer. Cancer Chemother Pharmacol.
81:1017–1023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami
H: Real-world treatment outcomes among patients with metastatic
pancreatic cancer in Japan: The Tokushukai real-world data project.
Mol Clin Oncol. 19:982023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buzby GP, Mullen JL, Matthews DC, Hobbs C
and Rosato EF: Prognostic nutritional index in gastrointestinal
surgery. Am J Surg. 139:160–167. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dolan RD, McSorley ST, Horgan PG, Laird B
and McMillan DC: The role of the systemic inflammatory response in
predicting outcomes in patients with advanced inoperable cancer:
Systematic review and meta-analysis. Crit Rev Oncol Hematol.
116:134–146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shimoyama R, Imamura Y, Uryu K, Mase T,
Fujimura Y, Hayashi M, Ohtaki M, Ohtani K, Shinozaki N and Minami
H: Real-world outcomes of systemic therapy in Japanese patients
with cancer (Tokushukai REAl-world data project: TREAD): Study
protocol for a nationwide cohort study. Healthcare (Basel).
10:21462022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Eba J and Nakamura K: Overview of the
ethical guidelines for medical and biological research involving
human subjects in Japan. Jpn J Clin Oncol. 52:539–544. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
National Cancer Registry (Ministry of
Health, Labour and Welfare), tabulated by Cancer Information
Service, National Cancer Center, Japan, . https://ganjoho.jp/reg_stat/statistics/data/dl/en.htmlApril
1–2023
|
|
16
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
17
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fairclough E, Cairns E, Hamilton J and
Kelly C: Evaluation of a modified early warning system for acute
medical admissions and comparison with C-reactive protein/albumin
ratio as a predictor of patient outcome. Clin Med (Lond). 9:30–33.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakahara K, Monden Y, Ohno K, Fujii Y,
Hashimoto J, Kitagawa Y and Kawashima Y: Importance of biologic
status to the postoperative prognosis of patients with stage III
nonsmall cell lung cancer. J Surg Oncol. 36:155–160. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wilcox RA, Ristow K, Habermann TM, Inwards
DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM,
Witzig TE, et al: The absolute monocyte and lymphocyte prognostic
score predicts survival and identifies high-risk patients in
diffuse large-B-cell lymphoma. Leukemia. 25:1502–1509. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Proctor MJ, McMillan DC, Morrison DS,
Fletcher CD, Horgan PG and Clarke SJ: A derived neutrophil to
lymphocyte ratio predicts survival in patients with cancer. Br J
Cancer. 107:695–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Watt DG, Proctor MJ, Park JH, Horgan PG
and McMillan DC: The neutrophil-platelet score (NPS) predicts
survival in primary operable colorectal cancer and a variety of
common cancers. PLoS One. 10:e01421592015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dolan RD, McSorley ST, Park JH, Watt DG,
Roxburgh CS, Horgan PG and McMillan DC: The prognostic value of
systemic inflammation in patients undergoing surgery for colon
cancer: comparison of composite ratios and cumulative scores. Br J
Cancer. 119:40–51. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dolan RD, Alwahid M, McSorley ST, Park JH,
Stevenson RP, Roxburgh CS, Horgan PG and McMillan DC: A comparison
of the prognostic value of composite ratios and cumulative scores
in patients with operable rectal cancer. Sci Rep. 10:179652020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kasymjanova G, MacDonald N, Agulnik JS,
Cohen V, Pepe C, Kreisman H, Sharma R and Small D: The predictive
value of pre-treatment inflammatory markers in advanced
non-small-cell lung cancer. Curr Oncol. 17:52–58. 2010.PubMed/NCBI
|
|
27
|
Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen
H, Liu L, Meng Z, Wang P and Chen Z: A novel systemic inflammation
response index (SIRI) for predicting the survival of patients with
pancreatic cancer after chemotherapy. Cancer. 122:2158–2167. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Müller L, Hahn F, Mähringer-Kunz A, Stoehr
F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler
J, et al: Immunonutritive scoring for patients with hepatocellular
carcinoma undergoing transarterial chemoembolization: Evaluation of
the CALLY index. Cancers (Basel). 13:50182021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Comparison of an inflammation-based
prognostic score (GPS) with performance status (ECOG) in patients
receiving platinum-based chemotherapy for inoperable non-small-cell
lung cancer. Br J Cancer. 90:1704–1706. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McMillan DC, Crozier JEM, Canna K,
Angerson WJ and McArdle CS: Evaluation of an inflammation-based
prognostic score (GPS) in patients undergoing resection for colon
and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Toiyama Y, Miki C, Inoue Y, Tanaka K,
Mohri Y and Kusunoki M: Evaluation of an inflammation-based
prognostic score for the identification of patients requiring
postoperative adjuvant chemotherapy for stage II colorectal cancer.
Exp Ther Med. 2:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferrucci PF, Ascierto PA, Pigozzo J, Del
Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P,
Savoia P, Mandalà M, et al: Baseline neutrophils and derived
neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic
melanoma patients receiving ipilimumab. Ann Oncol. 27:732–738.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weide B, Martens A, Hassel JC, Berking C,
Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di
Giacomo AM, et al: Baseline biomarkers for outcome of melanoma
patients treated with pembrolizumab. Clin Cancer Res. 22:5487–5496.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang L, Han H, Zhou L, Chen X, Xu Q, Xie
J, Zhan P, Chen S, Lv T and Song Y: Evaluation of the lung immune
prognostic index in non-small cell lung cancer patients treated
with systemic therapy: A retrospective study and meta-analysis.
Front Oncol. 11:6702302021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Gong X, Sun L, Miao L and Zhou Y:
The predictive value of pretreatment lactate dehydrogenase and
derived neutrophil-to-lymphocyte ratio in advanced non-small cell
lung cancer patients treated with PD-1/PD-L1 inhibitors: A
meta-analysis. Front Oncol. 12:7914962022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Banna GL, Di Quattro R, Malatino L,
Fornarini G, Addeo A, Maruzzo M, Urzia V, Rundo F, Lipari H, De
Giorgi U and Basso U: Neutrophil-to-lymphocyte ratio and lactate
dehydrogenase as biomarkers for urothelial cancer treated with
immunotherapy. Clin Transl Oncol. 22:2130–2135. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ,
Hong JG and Li T: The prediction potential of the pretreatment lung
immune prognostic index for the therapeutic outcomes of immune
checkpoint inhibitors in patients with solid cancer: A systematic
review and meta-analysis. Front Oncol. 11:6910022021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Strijker M, van Veldhuisen E, van der
Geest LG, Busch OR, Bijlsma MF, Mohammad NH, Homs MY, van Hooft JE,
Verheij J, de Vos-Geelen J, et al: Readily available biomarkers
predict poor survival in metastatic pancreatic cancer. Biomarkers.
26:325–334. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ahmad J, Grimes N, Farid S and
Morris-Stiff G: Inflammatory response related scoring systems in
assessing the prognosis of patients with pancreatic ductal
adenocarcinoma: A systematic review. Hepatobiliary Pancreat Dis
Int. 13:474–481. 2014. View Article : Google Scholar : PubMed/NCBI
|
